Back to search results

Innocell Immunotherapy for Recurrent Ovarian Cancer

This study is testing a new treatment called Innocell Autologous Cellular Immunotherapy for women with recurrent epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancer. This treatment uses your own cells to help your body fight the cancer. You might be able to join if you are at least 18 years old, have received at least one platinum-based chemotherapy, and single-agent therapy is appropriate for your next treatment. The main goals of this study are to see if the Innocell treatment can be successfully made from your cells and to check for any side effects. The study is currently unclear about its recruitment status.

Study design
This is a Phase 1, open-label study, meaning both you and your doctors will know which treatment you are receiving. It plans to enroll 8 participants.
What's involved
You will have a tumor biopsy to collect tissue for making the Innocell treatment. If successful, you will receive three doses of Innocell, given as an injection under the skin every two weeks.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored from your first dose of Innocell until 30 days after your last dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06366490

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

Recruiting
PHASE1Ages 18+InterventionalTreatment
PhotonPharma, Inc.
~8 participants
Updated 2026-03-27 on ClinicalTrials.gov
What's tested:Innocell Autologous Cellular Immunotherapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Success rate of autologous manufacturing
Measured over 2 months
+1 more outcome measured

Conditions

Ovarian Cancer
Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer

Explore related trials

Fallopian Tube CarcinomaMalignant Ovarian NeoplasmPrimary Peritoneal Cancer

Where it's being run

1 sites across 1 states
California1

Who to contact

Beth Crump, RN, BSN
[email protected]
303-981-1120
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Type 1 diabetes (if stable, well controlled, and not brittle); Vitiligo; Hypo- or hyperthyroid disease; or Autoimmune alopecia. 4. Treatment with systemic steroids or any other form of immunosuppressive therapy within 14 days prior to planned initiation of the Innocell vaccine; Note: Inhaled or topical steroids, including mouthwash, and adrenal replacement doses are permitted in the absence of active autoimmune disease. 5. Has any acute infection that requires specific therapy. Acute therapy must be completed at least 7 days prior to initiation of Innocell series; 6. Has received any live or attenuated vaccines against infectious diseases within 28 days of the planned vaccine initiation. Inactive vaccines, including SARS-CoV-2 vaccines authorized for use for active immunization to prevent COVID-19 are allowed and must be given in accordance with the prevailing immunization guidelines; or 7. Has received any other investigational agents within 4 weeks of planned vaccine initiation. 8. Hs received treatment with an approved systemic therapy within 3 weeks of planned vaccine initiation; 9. Prior malignancy, except those that were treated curatively and have not recurred within 5 years prior to study treatment; resected basal cell and squamous cell skin cancers; 10. History or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the patient's participation for the full duration of the study, such that it is not in the best interest of the patient to participate, in the opinion of the treating investigator; or 11. Inability of the subject to comply with study procedures and/or followup.

What this trial measures

  • Success rate of autologous manufacturing2 months

    Percent success rate to manufacture Innocell from autologous malignant tissue for patient administration

  • Safety assessed by treatment emergent adverse eventsFrom 1st dose of Innocell until 30 days post last dose

    Proportion of subjects experiencing treatment emergent adverse events